AI safety researcher Roman Yampolskiy breaks down his P(doom) estimate and why he believes artificial superintelligence could be a death sentence for humanity if development keeps moving this fast. His warning isn't anti-AI — it's a case for keeping AI as a tool we control, not a replacement for human judgment.Watch the full episode: https://open.spotify.com/episode/2R7oKzVSOWTR5079TYrZsg?si=302dfca33e9f4c04

Save 20% on all Nuzest Products WORLDWIDE with the code MIKKIPEDIA at www.nuzest.co.nz, www.nuzest.com.au or www.nuzest.comEpisode SummaryPaul Booth, sports nutritionist, exercise physiologist and PhD researcher in ultra-running metabolism, is back on Mikkipedia, straight from UTMB week in Chamonix, where he raced OCC and worked with elite athletes. Mikki and Paul pick up where they left off a year ago, talking about how much carbohydrate trail and ultra runners actually need. Paul shares

Bu bölümde, Endonezya'nın Helal Ürün Güvencesi Ajansı'nın (BPJPH) Sınıf A tıbbi cihazlar için 17 Ekim 2026'da yürürlüğe girecek olan zorunlu Helal sertifikasyonu gerekliliğini inceliyoruz. Hangi cihazların etkilendiğini, hayvansal kökenli materyallerin rolünü, uyumluluk sürecini ve üreticilerin bu yeni düzenlemeye hazırlanmak için atması gereken pratik adımları ele alıyoruz.Key Questions: - Endonezya'nın yeni Helal sertifikasyon zorunluluğu hangi tıbbi cihazları etkiliyor? - Sınıf A cihazlar için

Detta avsnitt behandlar den kommande tidsfristen för obligatorisk Halal-certifiering för medicintekniska produkter i klass A i Indonesien, satt till den 17 oktober 2026. Vi diskuterar kraven från Indonesiens Byrå för halalproduktgaranti (BPJPH) och förklarar varför denna nya regel, som börjar med lågriskprodukter, utgör en betydande utmaning för tillverkare. Lyssna för att förstå vilka produkter som påverkas, de specifika skyldigheterna och de praktiska steg ditt företag måste ta nu för att

Neste episódio, analisamos o prazo obrigatório de certificação Halal da Indonésia, a 17 de outubro de 2026, para dispositivos médicos de Classe A. A Agência de Garantia de Produtos Halal (BPJPH) exige que os fabricantes de dispositivos de baixo risco que utilizem materiais de origem animal obtenham a certificação para manter o acesso ao mercado. Discutimos quem é afetado, as etapas complexas do processo de certificação e as graves consequências da não conformidade. Oferecemos passos práticos para as

В этом выпуске мы обсуждаем предстоящий крайний срок, 17 октября 2026 года, для халяльной сертификации медицинских изделий класса А в Индонезии. Мы рассмотрим требования Агентства по обеспечению халяльной продукции (BPJPH) для изделий, содержащих материалы животного происхождения, и объясним, почему этот первый этап поэтапного внедрения является серьезной проблемой для производителей.Key Questions: - Какой крайний срок для халяльной сертификации медицинских изделий класса А в Индонезии? - Какие

Episode ini membahas tenggat waktu penting pada 17 Oktober 2026, untuk sertifikasi Halal wajib bagi perangkat medis Kelas A di Indonesia. Kami menguraikan persyaratan dari Badan Penyelenggara Jaminan Produk Halal (BPJPH), menjelaskan mengapa produsen perangkat berisiko rendah harus segera bertindak, dan memberikan langkah-langkah praktis untuk meninjau produk, mengaudit rantai pasokan, dan mempersiapkan kepatuhan untuk mempertahankan akses pasar di Indonesia.Key Questions: - Kapan batas waktu

We were delighted to be joined by two highly experienced leaders in the biotechnology industry, Howard Berman, Ph.D., and Kia Motesharei, Ph.D.Both Howard and Kia have built impressive careers across biotechnology, capital markets, business development and strategic transactions, with a track record of helping companies navigate some of the most important stages of their growth.Howard is now CEO of ReAlta Life Sciences, where he is leading the company through an important clinical-stage period as it

Telegram - t.me/oksluhaiМонобанка - https://send.monobank.ua/jar/8BNT9MPgPPKo-Fi - https://ko-fi.com/blindspotsystemsСліпа Зона на Spotify - https://open.spotify.com/show/5WBg3tbdebU1nHa9JPhnZw?si=6e546bc4b19e4e3cО!ПОЛіТИЧНО на Spotify - https://open.spotify.com/show/033Z39Ub63Wc8SriiNz88p?si=6627bd0bffc7411bМи не пірати, Луффі на Spotify - https://open.spotify.com/show/1r56bfembTUtqygPLzRoZw?si=00a9eb8796a6451eОкей, Слухай! на Spotify -

Industry is using AI to surface hidden patterns and accelerate decision-making in high-pressure launch environments.In a new pharmaphorum podcast, host Nicole Raleigh speaks with Jason Smith, CTO of AI and analytics at Within3, for a conversation on data-fuelled agile launches and smarter decision-making. Smith discusses alignment of cross-functional teams and fostering real collaboration and efficiency, how pharma teams can use real-time data to shape more precise and effective launch strategies,

The scarecrow watches over the field, but does it watch us back? Does it keep the birds away, or does it deter darker fiends from these haunted lands? Join Robert and Joe for a Halloween-season look at the science, culture and folklore of scarecrows.See omnystudio.com/listener for privacy information.

Повний епізод 8 жовтня«Залишаюсь заради дітей» звучить як подвиг. А чи перевіряв хтось, що діти насправді отримують від такого дому?Двоє ведучих сперечаються без компромісів. Одна сторона тримається за дані: у великому лонгітюдному дослідженні діти з низькоконфліктних шлюбів тяжче переживали розлучення. Друга показує діру в цих даних: «низький конфлікт» складають і щасливі пари, і ті, де давно нічого не відчувають. Про тихо мертві домівки наука майже мовчить.Після цього «лишаюсь заради них» перестає

Michael speaks with Tim Wu, the Columbia law professor and author of The Age of Extraction, about how media and tech platforms learned to harvest our attention, why convenience is among the most powerful forces of our time, and what the easy option can take from us. They discuss:(00:00) Cold open(01:12) Selling attention, from 1833 to now(07:46) Why phones are changing human evolution(16:20) Why ads adapt to every backlash(18:00) Attention merchants vs. extractors(25:48) Easiest wins: the power of

We’re all aware – and wary – of doomscrolling. Lots of screen time can be bad for us. But what if that’s not always the case? We spoke with the author of a study that found a positive relationship between screen time and brain development in young people. This episode, we sort through what to actually worry about when it comes to screen time – and what guidelines already exist that can empower you and the kids in your life.Interested in learning more about how screen time affects your brain? Email

The Pharma Closeout's EASD 2026 Debrief covers the readouts from the European Association for the Study of Diabetes meeting in Milan that matter for drug, device and payer strategy. The new ADA/EASD consensus reportmoves GLP-1 and SGLT2 drugs earlier in type 2 diabetes care, potentially from diagnosis, and prefers weight-lowering drugs for people with overweight orobesity. Lilly's ACHIEVE-4 put its oral GLP-1 pill Foundayo against insulin and met a heart-safety bar. Real-world data arrived

Genmab and AbbVie's investigational frontline Epkinly (epcoritamab) combination cut progression-or-death hazard 51% versus R-CHOP in lymphoma patients with IPI scores of 3–5; it did not face Polivy's approved regimen. Vaxcyte's VAX-31 met its pivotal immune-response framework, with two serotypes clearing only a looser threshold against Merck's CAPVAXIVE—not proof of disease prevention. Deals span GE HealthCare–SOFIE and PET tracer FAPI-74, Shionogi–IntraBio and AQNEURSA in rare

Carla Rothlin joins Immune at AAI2026 to talk about her career studying inflammation regulation and how she co-founded the Global Immunotalks virtual seminar series. Host: Cindy Leifer Guest: Carla Rothlin Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server TAM receptor signaling in immune homeostasis (Annu Rev Immunol, 2015) MerTk in retinal pigment epithelial cells (Sci Adv, 2023) Modifiers determine MerTk function (Elife,

You've perfected your process at the bench. Now comes the part that keeps CMC scientists up at night: will it still work at 2,000L? Right now, most teams find out the hard way, through failed runs, wasted batches, and months of delay to patients waiting on a therapy. Christian Witz believes there's a better way: use computational fluid dynamics to see how your cells will actually behave at full scale before you ever run the process, and stop treating scale-up as a guessing game. On this episo...

In this special episode, in partnership with Frontiers Science House, we launch our new Why? series by asking one of the biggest questions of our time: Why AI? Why has artificial intelligence advanced so rapidly, why does it work the way it does, and why could it fundamentally change how we think, work, and live? To explore the answers, we hear from four remarkable voices at the heart of the AI conversation: Geoffrey Hinton, Mike Wooldridge, Cristina Criddle, and Wendy Hall. Like this podcast

Pharma partnering in China is getting earlier and broader, with Merck & Co., Novo Nordisk and Novartis striking multibillion-dollar deals for assets spanning new modalities and disease areas. On the latest BioCentury This Week podcast, BioCentury's analysts assess the trend and why co-development deals could draw scrutiny in Washington. The analysts also discuss the complexities of Beam's trade secret suit against YolTech, why the GLOBE Medicare pricing model matters more for the preceden...